Global Immunotalks
Profile Url: global-immunotalks
Virtual seminars in immunology. Launched by Carla Rothlin and Elina ZĂșñiga @ZunigaLab
1.2K
185
33
Presentation at Global Immunotalks
Paper
Publisher's Page
Preprint Page
Severe cases of COVID-19 are characterized by a strong inflammatory process that may ultimately lead to organ failure and patient death. The NLRP3 inflammasome is a molecular platform that promotes inflammation via cleavage and activation of key inflammatory molecules including active caspase-1 (Casp1p20), IL-1ÎČ and IL-18. Although the participation of the inflammasome in COVID-19 has been highly speculated, the inflammasome activation and participation in the outcome of the disease is unknown. Here we demonstrate that the NLRP3 inflammasome is activated in response to SARS-CoV-2 infection and it is active in COVID-19, influencing the clinical outcome of the disease. Studying moderate and severe COVID-19 patients, we found active NLRP3 inflammasome in PBMCs and tissues of post-mortem patients upon autopsy. Inflammasome-derived products such as Casp1p20 and IL-18 in the sera correlated with the markers of COVID-19 severity, including IL-6 and LDH. Moreover, higher levels of IL-18 and Casp1p20 are associated with disease severity and poor clinical outcome. Our results suggest that the inflammasome is key in the pathophysiology of the disease, indicating this platform as a marker of disease severity and a potential therapeutic target for COVID-19.
1.1K
58
181
Talk by Dr. Richard Flavell
GLOBAL IMMUNOTALK 01-13-2021
1.0K
559
216
Talk by Dr. Emily Troemel
GLOBAL IMMUNOTALK 09-23-2020
1.0K
492
141
Talk by Dr. Katrin Mayer-Barber
GLOBAL IMMUNOTALK 10-14-2020
915
429
126
Talk by Dr. Richard Locksley
GLOBAL IMMUNOTALK 12-09-2020
840
90
188
Talk by Dr. Ido Amit
GLOBAL IMMUNOTALK 11-25-2020
Loading Projects...